2 October 2018 - Deborah Wilkes
Archived
A court in the US has ruled that Germany's Fresenius can terminate its planned USD4.75 billion acquisition of US generics, OTC and animal health company Akorn.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.